ARM A (patients not taking CYP3A4 inhibitors)
ARM B (patients taking CYP3A4 inhibitors)
Patients should have
Primary Outcome Measures :
1.Determine Optimal Biologic Dose (OBD)
Determine the OBD of BMF-219 monotherapy.
Secondary Outcome Measures :
1.Evaluate the Safety by treatment-emergent TEAEs and SAEs
Evaluate the safety BMF-219 as expressed by treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs).
Check out our study here: https://clinicaltrials.gov/ct2/results?cond=&term=BMF-219&cntry=&state=&city=&dist=